Compare BHRB & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHRB | ODTX |
|---|---|---|
| Founded | 1852 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 968.8M | 875.1M |
| IPO Year | 2023 | 2025 |
| Metric | BHRB | ODTX |
|---|---|---|
| Price | $72.79 | $20.78 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $71.80 | N/A |
| AVG Volume (30 Days) | 114.9K | ★ 173.5K |
| Earning Date | 04-23-2026 | N/A |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | ★ 173.76 | N/A |
| EPS | ★ 2.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.62 | N/A |
| Revenue Next Year | $10.06 | N/A |
| P/E Ratio | $33.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.42 | $15.10 |
| 52 Week High | $75.09 | $23.08 |
| Indicator | BHRB | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 54.42 |
| Support Level | $60.93 | $15.10 |
| Resistance Level | $74.06 | N/A |
| Average True Range (ATR) | 1.54 | 1.70 |
| MACD | -0.18 | 0.19 |
| Stochastic Oscillator | 55.03 | 49.67 |
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.